Clinical Trials Logo

Clinical Trial Summary

this is a single-arm, open, multicenter, phase 2 study to evaluate the efficacy, safety and pharmacokinetics of HYLM-122 monotherapy in Chinese subjects with FLT3 positive relapsed or refractory acute myeloid leukemia.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05241106
Study type Interventional
Source Tarapeutics Science Inc.
Contact Yang Shu, MD. BS.
Phone 86-13918983465
Email shuyang@tarapeutics.com
Status Recruiting
Phase Phase 2
Start date September 29, 2021
Completion date June 30, 2026

See also
  Status Clinical Trial Phase
Terminated NCT04113616 - An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) Phase 1/Phase 2
Recruiting NCT05241093 - A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT02074839 - Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation Phase 1
Terminated NCT05345938 - A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia Phase 1/Phase 2
Terminated NCT03218683 - Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies. Phase 1